Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by MMABStraderon Nov 08, 2023 7:50pm
165 Views
Post# 35724978

RE:x sites, y patients, always underwhelming

RE:x sites, y patients, always underwhelming
The higher the "better than expectations result" during the test, the bigger the market/acceptance for the treatment once FDA approval is received.

Also, if the FDA doesn't stop the test at the mid point of 90 test participants, if the results of the test shows siginificant proof of exceeding expextations, then it's my belief that there is a good chance the FDA stop the test whan an additional 10 or 20 or 30 more people are enrolled in the test and assuming test results are still exceeding expectations.

Just because the test isn't stopped at the mid point, it doesn't mean that the test has to run to completion.

There is the possibility that the test shows exceeding epectations at the mid point, possily at the end of February, and the test continues to run and when another 15 or 20 test participants are enrolled with exceeding expectations results, the FDA may stop the test at that point???
<< Previous
Bullboard Posts
Next >>